Prescription drug management, walked through 4 constructed note lines

“Refilled” is not a decision: a note that says only that can leave a visit with no prescription drug management credit at all.

That credit carries weight. Under the 2023 AMA E/M guidelines, prescription drug management is an example of moderate risk. Moderate risk is part of what can support a 99214. If the note doesn’t show the decision, a reviewer may not count it.

Good prescription drug management documentation shows four things: the drug and dose, the decision, the reason, and the problem it treats. Medicare contractor First Coast lists nearly the same four elements.

Below are four constructed note lines, a refill, a continuation, a dose change, and a stop, each shown before and after. By the end, you’ll be able to write the line a reviewer can credit.

What is prescription drug management in E/M?

Prescription drug management is a decision you make about a prescription drug during the visit and record in the note. The 2023 AMA E/M guidelines list it as an example of moderate risk in the medical decision making table. The AMA does not define the term, so Medicare contractors fill in the detail.

In the AMA’s table of medical decision making levels, the risk column is labeled “Examples only.” Prescription drug management sits in the moderate row. It is an example of the kind of decision that carries moderate risk, not a box that turns moderate the moment a drug appears.

Risk covers the options you weighed, not only the one you picked. The AMA guidelines include “the possible management options selected and those considered but not selected after shared decision making with the patient and/or family.” CGS, the Medicare contractor for Jurisdiction 15, applies that to drugs in its 2021 E/M questions and answers: “You can also count prescription medications considered but not given.”

That second point gets missed. A drug you discussed and decided against can count, when the note says you considered it and why you didn’t start it.

Since 2021, office visit levels rest on medical decision making or total time, per the AMA’s E/M guidance. Medical decision making has three elements: problems addressed, data reviewed, and risk. Two of the three set the level. Prescription drug management feeds only one of them.

What doesn’t count as prescription drug management?

A medication list does not count. Neither does a refill documented with no problem addressed, an over the counter drug on its own, or an injection ordered for the patient. Each appears in Medicare contractor guidance. What they share is a note that records a drug without recording a decision about it.

Here is how three contractors put it.

•       The medication list. Noridian: “Simply listing current medications is not considered ‘prescription drug management.’”

•       The bare refill. First Coast: an encounter “documented solely as a prescription refill, without documentation of a problem addressed or managed, may not support prescription drug management for MDM purposes.”

•       The bare refill, again. CGS: “An encounter documented as only a prescription refill without documentation of a problem addressed would not suffice.”

•       Over the counter drugs. First Coast: “Over the counter (OTC) medications do not qualify as prescription drug management.”

•       Injections. CGS: “Ordering an injection for the patient is not prescription drug management.”

 

“Reviewed” has the same problem. In its 2021 E/M FAQ, CGS says that only documenting “reviewed” on the medication list does not support prescription drug management.

I read notes like these from the payer side. A list tells me what the patient takes. It doesn’t tell me what you decided.

What does a prescription drug management note need to show?

A prescription drug management note needs to show the drug and dose, the decision, the reason for it, and the problem it treats. The decision can be to start, continue, change, or stop a drug, or to decide against one. A change in dose is not required.

First Coast spells this out. To qualify for credit under MDM, it says documentation should clearly identify:

1.     “The medication involved. The drug name and dosage must be specified.”

2.     “The provider’s medical decision (e.g., ‘continue,’ ‘increase,’ ‘discontinue’).”

3.     “The reason for the decision.”

4.     “How the decision relates to the patient’s current condition and treatment plan.”

 

You don’t have to change anything for the decision to count. CGS says prescription drug management “does not require a new drug, a new dosage, or a discontinuation of a current prescription.” First Coast lists “Continuing an existing prescription after evaluating the patient’s condition” as an example.

The catch is the word evaluating. Noridian says “a decision to maintain a current medication or dosage would need to be supported in documentation that the provider evaluated the medications.” A continuation holds up when the note shows you checked whether the drug was working.

That is why the reason carries the most weight. “Continue lisinopril” is an instruction. “BP 128/78 today, at goal, continue lisinopril 20 mg daily” shows an evaluation.

What do prescription drug management examples look like?

The examples below show four common medication decisions, each written two ways. The before line records a drug. The after line records a decision: the drug and dose, what you decided, why, and the problem it treats. All four are constructed for teaching. None comes from a real patient or a real note.

Prescription drug management: four constructed note lines, before and after Constructed for teaching. None comes from a real patient or a real note.
Decision Before: records a drug After: records a decision What the after line adds
Refill Refill lisinopril. Hypertension, BP 128/78 today, at goal. Continue lisinopril 20 mg daily, refilled for 90 days. The problem, its status, the dose, and the decision to continue.Contested: contractors differ on a stable drug continued at the same dose.
Continue Afib, stable. Continue meds. Atrial fibrillation, rate controlled, resting HR 74 today. Reports mild fatigue. Considered lowering metoprolol succinate; continued 50 mg daily to keep rate controlled. Recheck fatigue at next visit. The drug and dose, the evaluation, and an option considered but not selected.
Adjust DM2, A1c up. Metformin. Type 2 diabetes, A1c 8.1% today, up from 7.2%. Increase metformin from 500 mg twice daily to 1,000 mg twice daily. Recheck A1c in 3 months. The change, the reason for it, and the plan to check whether it worked.
Stop Myalgia. Stopped statin. Hyperlipidemia. New thigh myalgia since starting atorvastatin 40 mg daily; CK normal today. Stop atorvastatin. Reassess symptoms in 4 weeks, then discuss another statin. Which drug, why it was stopped, and what happens next.

Every after line follows the same order. The problem and its status come first, then the drug and dose, then the decision and the reason. A reviewer reads the decision against the problem, so the problem has to sit in the same line.

The continuation row also records an option considered and not selected. The AMA counts those options as part of risk, and it costs one sentence to write.

The refill row is the contested one. It documents a decision, which First Coast and Noridian ask for. CGS has said a stable drug at goal, continued at the same dose, does not count. The section on contractors below covers that split.

Want this habit built into every visit level? The Coding Nurse® is building a seven-module E/M documentation training for NPs and PAs on the AMA framework. Join the E/M documentation training waitlist to hear first when enrollment opens.

Does prescription drug management make a visit a 99214?

Not on its own. Prescription drug management can support moderate risk, but two of the three medical decision making elements set the level. For an established patient 99214, you also need moderate problems or moderate data. A drug decision supports one element, not the whole visit.

First Coast puts it plainly: “Prescription drug management alone does not establish the final MDM level.”

Noridian makes a related point. In a May 2025 provider Q&A, it advised looking at the whole visit “before assuming that prescription drug management is always going to be moderate.”

Getting this right matters in both directions. In 2024 national Medicare data, a 99214 averaged $34.34 more in allowed amount than a 99213. A visit that supports moderate medical decision making and gets billed a level low leaves that difference behind.

The other direction is where audits look. Medicare’s 2025 CERT supplemental data projected $853.7 million in improper payments on established patient office visits. The top root cause was documentation that supported a lower level than the one billed.

A line that names the decision protects you either way. It supports the level you earned, and it holds up when someone checks.

When does a medication decision become high risk?

A medication decision can reach high risk when the drug needs intensive monitoring for toxicity. The 2023 AMA guidelines list drug therapy requiring intensive monitoring for toxicity as a high risk example. The definition is narrow, and the note has to show that the monitoring is for toxicity.

The AMA definition starts with the drug itself: “A drug that requires intensive monitoring is a therapeutic agent that has the potential to cause serious morbidity or death.”

Two limits follow in the same definition. “Monitoring by history or examination does not qualify.” And for long-term use, “Long-term intensive monitoring is not performed less than quarterly.”

The note has to connect the test to the drug. In its May 2025 Q&A, Noridian said: “If the lab order does not indicate the (drug name) monitoring, this may not be considered for the E/M risk element.”

So a lab order on its own is a test. A lab order that names the drug and the toxicity it checks for is risk.

Which drugs qualify is a clinical question and a contractor question, so this post doesn’t list them. Check the AMA definition and your contractor’s guidance for the drug in front of you.

Do Medicare contractors agree on what counts?

Not fully. The AMA does not define prescription drug management, so each Medicare contractor writes its own guidance. They agree that a list or a bare refill does not count. They differ on a line many notes carry: a stable drug, continued at the same dose.

First Coast counts “Continuing an existing prescription after evaluating the patient’s condition.” Noridian asks for documentation “that the provider evaluated the medications.” Both lean on the evaluation.

CGS has answered the question both ways. In its 2021 E/M FAQ, one answer says a stable hypertension drug at goal, continued at the same dose, does not count. Another says, “A decision to maintain the current medication is sufficient,” as long as the documentation shows decision making took place.

That is the honest limit of this post. The four-part line makes a continuation defensible. It cannot promise that every contractor will credit it. Read your own contractor’s guidance, and ask your compliance officer how your organization applies it.

One more limit. If you bill the visit on total time, none of this sets the level. Noridian: “If determining the level of E/M code based on total time, the MDM elements would not apply.”

Prescription drug management FAQ

Does reviewing the medication list count as prescription drug management?

No. Noridian’s guidance is direct: “Simply reviewing a medication list does NOT constitute prescription drug management.” Medication reconciliation is still good care. It just isn’t a decision. The credit comes from what you decided about a specific drug and why you decided it.

Does a refill count as prescription drug management?

A refill can count when the note shows the problem you addressed and the decision behind the refill. A refill documented with nothing else may not. First Coast and CGS both tie refill credit to a documented problem. Write the problem, its status, the drug and dose, and why you are continuing it.

Do over the counter medications count?

Not on their own. First Coast says “Over the counter (OTC) medications do not qualify as prescription drug management.” CGS adds that managing a patient’s prescription drugs when you add an OTC drug or supplement can show prescription drug management. The credit comes from the prescription drug decision.

Does prescription drug management matter if I bill on total time?

Not for the level. When you choose the office visit level by total time, the medical decision making elements, risk included, do not set the code. Noridian says the MDM elements would not apply. Document the medication decision anyway. It is part of the care you gave, and the note still has to show it.

Is prescription drug management always moderate risk?

No. The AMA table lists it as one example of moderate risk, under the label “Examples only.” Noridian cautions against “assuming that prescription drug management is always going to be moderate.” The documented decision and the patient in front of you decide the risk, and the level still needs two of three elements.

Start with your next refill

Pick one refill on tomorrow’s schedule and write it in four parts: the problem and its status, the drug and dose, the decision, and the reason. For the full framework behind that line, join the E/M documentation training waitlist.

This is general education based on the published guidelines. Your compliance officer and your payer policy govern your specific case. The note lines in this post are constructed for teaching and do not come from any patient record.

Jesse Gallop, LPN, CDIP, CCS, CCS-P, CPMA

Jesse Gallop is an LPN who left the floor for medical coding, CDI, DRG validation, and auditing. He now reviews inpatient claims from the payer side for Medicare, Medicare Advantage, Medicaid, and commercial plans. AHIMA-Approved Trainer and AAPC-Approved Instructor. He founded The Coding Nurse® to teach other nurses the documentation rules from the side that decides them.

Next
Next

Inpatient Coding vs DRG Validation: 7 Differences that Change the Job